Wiley Bunn, MD
Gynecologic Oncology · Syracuse, NYNPI 1902982473
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,450 of the $200,821 with a category attached, or 78.4%. 20 manufacturers reported payments, led by GSK at 59.1% of the total. Reporting peaked in 2024 at $58,789 and has fallen 65.7% since, to $20,150 in 2025. Among gynecologic oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $888.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$119K
- Clovis Oncology, Inc.$32K
- AstraZeneca$26K
- Tesaro, Inc.$20K
- Medical Device Business Services, Inc.$1K
- AbbVie$418
- plus $2K from 14 others
What the payments were for
- Consulting fees$9,2005%
- Speaking & faculty fees$157,45078%
- Travel & lodging$26,33413%
- Food & beverage$7,5824%
- Education$2550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 90 | $118,720 |
| Clovis Oncology, Inc. | 31 | $32,082 |
| AstraZeneca | 31 | $26,316 |
| Tesaro, Inc. | 26 | $19,572 |
| Medical Device Business Services, Inc. | 7 | $1,406 |
| AbbVie | 5 | $418 |
| Myriad Genetic Laboratories, Inc. | 7 | $405 |
| Genmab U.S., Inc. | 3 | $348 |
| Merck | 7 | $233 |
| Immunogen, Inc. | 2 | $226 |
| Eisai Inc. | 2 | $214 |
| TELA Bio, Inc. | 1 | $210 |
| Amgen | 3 | $132 |
| Intuitive Surgical | 1 | $120 |
| Lupin Inc. | 1 | $102 |
| Seagen Inc. | 1 | $100 |
| Therapeuticsmd, Inc. | 2 | $97 |
| Kyowa Kirin, Inc. | 4 | $84 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$200,821 in reported general payments places this provider in the 95th percentile of 154 gynecologic oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Medroxyprogesterone Acetate | 24 | $116 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Syracuse
- Heidi GodoyAlbany$1.1M
- Bhavana PothuriNew York$366K
- Joyce BarlinAlbany$208K
- Ghadir SalameBrooklyn$179K
- Richard MooreRochester$124K
- Mario LeitaoNew York$116K
- Konstantin ZakashanskyNew York$93K
- Evelyn CantilloNew York$79K
- Farr NezhatNew York$41K
- Kristen ZeligsNew York$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.